New Collaborations and Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma to Establish US Operations

Santaris PharmaAppoints Art Levin Ph.D. as President of US Operations and Chief Development Officer

18-Sep-2009 - USA

Santaris Pharma A/S announced it has established operations in the United States. Increasing interest, new collaborations and breakthrough advancements utilizing the Company's proprietary RNA-based Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine led Santaris Pharma A/S to establish US-based operations inSan Diego, California.

To spearhead the US expansion, Santaris Pharma A/S has appointed Arthur A. Levin, PhD, as President of its US operations. In addition, Dr. Levin will hold global responsibility as Vice President and Chief Development Officer of Santaris Pharma A/S.

Dr. Levin has 15 years of experience in RNA-based research and more than 25 years of experience in the pharmaceutical industry. Prior to joining Santaris Pharma A/S, Dr. Levin was Senior Vice President of Drug Development at Isis Pharmaceuticals where he was instrumental in advancing more than a dozen RNA-based antisense drugs from basic research to clinical development.

https://www.bionity.com/en/news/106421/new-collaborations-and-advancements-in-rna-based-drug-development-programs-lead-santaris-pharma-to-establish-us-operations.html